Therefore, it is plausible that LY6D may exert other, possibly a preponderance of tumour promoting, biological effects in these tumours, similar to observations made in e.g. prostate cancer [17], or estrogen-receptor positive breast cancer [18]. This evidence concerns the gene ESR1 and prostate cancer.